Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Rating) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 258,200 shares, a decline of 5.6% from the August 31st total of 273,500 shares. Currently, 0.7% of the company's stock are short sold. Based on an average daily trading volume, of 196,600 shares, the days-to-cover ratio is presently 1.3 days. Harvard Bioscience Price Performance

HBIO opened at $2.56 on Monday. Harvard Bioscience has a 1-year low of $2.27 and a 1-year high of $8.23. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.42 and a quick ratio of 1.16. The business has a 50 day moving average of $3.19 and a 200-day moving average of $4.07.

Harvard Bioscience (NASDAQ:HBIO - Get Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The medical instruments supplier reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.01. Harvard Bioscience had a positive return on equity of 7.74% and a negative net margin of 3.03%. The company had revenue of $29.21 million during the quarter, compared to analysts' expectations of $30.10 million. On average, equities analysts expect that Harvard Bioscience will post 0.05 EPS for the current fiscal year. Insider Activity at Harvard Bioscience

In other news, Director Bertrand Loy purchased 17,291 shares of the stock in a transaction that occurred on Wednesday, August 24th. The stock was acquired at an average price of $3.23 per share, with a total value of $55,849.93. Following the purchase, the director now owns 382,116 shares in the company, valued at approximately $1,234,234.68. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO James W. Green bought 40,000 shares of the firm's stock in a transaction on Wednesday, August 17th. The stock was purchased at an average price of $3.19 per share, with a total value of $127,600.00. Following the completion of the transaction, the chief executive officer now directly owns 2,248,811 shares of the company's stock, valued at $7,173,707.09. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bertrand Loy bought 17,291 shares of the firm's stock in a transaction on Wednesday, August 24th. The shares were bought at an average cost of $3.23 per share, with a total value of $55,849.93. Following the transaction, the director now directly owns 382,116 shares of the company's stock, valued at $1,234,234.68. The disclosure for this purchase can be found here. In the last quarter, insiders bought 72,651 shares of company stock valued at $234,345. 6.20% of the stock is owned by corporate insiders. Institutional Investors Weigh In On Harvard Bioscience

Several hedge funds have recently modified their holdings of the business. Empirical Asset Management LLC acquired a new position in shares of Harvard Bioscience in the second quarter valued at $36,000. BNP Paribas Arbitrage SA raised its stake in shares of Harvard Bioscience by 47.6% in the second quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 3,200 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Harvard Bioscience in the second quarter valued at $37,000. Amalgamated Bank acquired a new position in shares of Harvard Bioscience in the first quarter valued at $38,000. Finally, Lazard Asset Management LLC raised its stake in shares of Harvard Bioscience by 68.4% in the second quarter. Lazard Asset Management LLC now owns 11,989 shares of the medical instruments supplier's stock valued at $43,000 after purchasing an additional 4,869 shares in the last quarter. 71.44% of the stock is owned by institutional investors. Analyst Upgrades and Downgrades

Separately, KeyCorp decreased their target price on Harvard Bioscience from $10.00 to $7.00 and set an "overweight" rating for the company in a research report on Friday, August 5th.About Harvard Bioscience (Get Rating)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.Read MoreGet a free copy of the StockNews.com research report on Harvard Bioscience (HBIO)Archer Daniels Midland: Dividend Hero With 49 Years Of IncreasesWill Fully Autonomous Tractors Make Deere the Tesla of Farming? Magna International is Your Auto and EV One-Stop Shop Stock Is the Bond Market Signaling a Market Bottom? EV Battery Maker Freyr Set For Major Global Expansion

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Harvard Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harvard Bioscience wasn't on the list.

While Harvard Bioscience currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Kirk McDonald shares three stocks from different industries with different market caps and explains why each is a holding in his portfolio.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.